Looking to clarify its expectations for manufacturer responses following inspections, the FDA earlier this year unveiled, for the first time, draft guidance on best practices for the industry when replying to the receipt of a Form 483.
FDA expectations create potential friction in new Form 483 response guidance
Latest from Blog
STAT+: Top lawmaker takes aim at doctor lobby, linking AMA’s billing codes to fraud fight
WASHINGTON — For decades, politicians have blamed the country’s biggest doctor lobby for some of the health care systems problems. Now it faces a new line of attack as Republicans portray their
Opinion: The cruise ship hantavirus outbreak is a warning sign to the U.S.
Three passengers are dead. Seven people are ill. The ship is anchored off Cape Verde, passengers cannot disembark, and the World Health Organization is coordinating the response. The suspected cause is hantavirus,
Supreme Court Puts Brakes on Abortion Pill Restrictions MedNews
MONDAY, May 4, 2026 The Supreme Court has temporarily stepped in to preserve nationwide access to the abortion pill mifepristone, halting a lower court ruling t Post Views: 0
FDA Green Lights Expanded Access to Pancreatic Cancer Drug, Daraxonrasib MedNews
MONDAY, May 4, 2026 The U.S. Food and Drug Administration (FDA) granted expanded access for the use of an experimental pancreatic cancer drug, daraxonrasib.This Post Views: 0
Supreme Court restores access to abortion pill mifepristone through telehealth, mail, and pharmacies
WASHINGTON — The Supreme Court on Monday restored broad access to the abortion pill mifepristone, blocking a lower-court ruling that had threatened to upend one of the main ways abortions are provided across the